Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance.
Overview
Parkinsonism describes bradykinesia with tremor, rigidity or other features; idiopathic Parkinson disease must be distinguished from drug-induced and atypical syndromes. Medicines primarily improve motor symptoms but do not yet reliably stop neurodegeneration. Treatment should balance mobility, cognition, falls, hallucinations and daily function [1,2].
Drug classification and mechanisms
- Levodopa plus carbidopa or benserazide: levodopa crosses the blood–brain barrier and is converted to dopamine; the peripheral dopa-decarboxylase inhibitor limits peripheral metabolism, nausea and hypotension.
- Dopamine receptor agonists: pramipexole, ropinirole, rotigotine and apomorphine stimulate dopamine receptors directly.
- MAO-B inhibitors: selegiline, rasagiline and safinamide reduce brain dopamine metabolism; safinamide also modulates glutamate release.
- COMT inhibitors: entacapone, opicapone and tolcapone prolong levodopa exposure; tolcapone has serious liver-toxicity restrictions.
- Amantadine: has dopaminergic and NMDA-antagonist actions; extended-release formulations can reduce levodopa-induced dyskinesia.
- Antimuscarinics: trihexyphenidyl or benztropine may reduce tremor in carefully selected younger patients but commonly worsen cognition and constipation [1].
Initial treatment and sequencing
The American Academy of Neurology recommends immediate-release levodopa as the preferred initial dopaminergic treatment for patients seeking symptomatic motor benefit in early Parkinson disease. Dopamine agonists generally yield less motor benefit and more hallucinations, somnolence and impulse-control disorders and should usually be avoided in older or cognitively vulnerable patients [2]. Exercise, physiotherapy and specialist review are important alongside medicine [1,2].
Wearing-off, dyskinesia and advanced disease
Progressive loss of dopaminergic terminals and pulsatile drug exposure can cause predictable wearing-off and dyskinesia. Responses include revising levodopa timing/formulation, adding MAO-B or COMT inhibitors, selected agonists, rescue apomorphine or device-aided options. Deep brain stimulation and infusion approaches are considered in carefully selected advanced disease. Abrupt withdrawal of dopaminergic drugs can cause severe rigidity and a hyperpyrexia syndrome [1].
Pharmacokinetics and interactions
Levodopa competes with large neutral amino acids for gut and CNS transport; high-protein meals may alter response in some patients. Dopamine antagonists such as metoclopramide and many antipsychotics can worsen parkinsonism. Pramipexole is substantially renally cleared; ropinirole has CYP1A2 interactions. MAO-B inhibitors can interact with serotonergic or sympathomimetic medicines depending on drug and dose; product-specific precautions matter [1].
Safety and clinical pearls
Levodopa can cause nausea, orthostasis, hallucinations and dyskinesias. Dopamine agonists can cause sudden sleep episodes, edema, hallucinations and compulsive behavior; counsel patients and carers. Antimuscarinics cause urinary retention, cognitive deterioration and glaucoma-related concerns. Avoid classifying selegiline principally as an alpha-2 antagonist or rotigotine as a new nonagonist category: both are misleading [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease: practice guideline summary. Neurology. 2021;97:942–957. doi:10.1212/WNL.0000000000012868. Available from: https://doi.org/10.1212/WNL.0000000000012868
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.